Acetic acid chromoendoscopy doubled suspicious lesions in Barrett's surveillance but found no more neoplasia

The edition in brief

The ACID trial, a stepped-wedge cluster randomised trial of 2,267 people under Barrett's surveillance at 18 Dutch community hospitals, found acetic acid chromoendoscopy flagged suspected lesions in 14% against 6% but did not raise neoplasia detection (7.4% vs 7.1%, OR 0.97). A phase 2b trial of oral icotrokinra, a peptide blocking the IL-23 receptor, in 252 adults with moderate to severe ulcerative colitis found week-12 clinical response of 55 to 63% across doses against 27% on placebo, and clinical remission of 30% at 400 mg against 11%. SIERRA, a single-arm phase 3b study of tremelimumab plus durvalumab in 111 patients with unresectable hepatocellular carcinoma and Child-Pugh B7 to B8 function, performance status 2 or main portal vein thrombosis, found grade 3 or 4 treatment-related adverse events in 20% and objective response in 14%. The FDA recorded a supplement on 25 September for the adalimumab biosimilar adalimumab-aqvh (Yusimry); the record does not describe the change. The pearl covers the Seattle biopsy protocol.